Effect of febuxostat in patients with chronic kidney disease

Effect of febuxostat in patients with chronic kidney disease - Effect of febuxostat in patients with chronic kidney disease

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000007481

Enrollment

Registered

2012-04-01

Start date

2012-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease, hyperuricemia

Interventions

1. Febuxostat group: Patients in this group are initially given 10mg of febuxostat once daily for 12 weeks. Dosage of febuxostat are allowed to increase up to 40mg daily for the target value (serum u

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Chronic kidney disease stage 3. 2. Serum uric acid equal and more than 7mg/dl.

Exclusion criteria

Exclusion criteria: 1. Patients with acute/chronic inflammatory disease and/or malignancy. 2. Patients with severe cardiovascular/respiratory/digestive disease within past 6 months. 3. Woman who is pregnant. 4. Patients who medicated with febuxostat and/or benzbromarone within past 3 months.

Design outcomes

Primary

Measure	Time frame
1. Urinary tubular markers 2. Urinary albumin excretion 3. Serum systatin C, eGFR	—

Countries

Japan

Contacts

Public ContactKenichi Tanaka

Fukushima Medical University Department of Nephrology, Hypertension, Diabetology, Endcrinology, and Metabolism

im3@fmu.ac.jp024-547-1206

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026